Aquestive Therapeutics GAAP EPS of -$0.07 beats by $0.07,...

2026-05-13 16:06:14 ET More on Aquestive Therapeutics Aquestive Therapeutics: Post-CRL Risk, Timeline, And Valuation Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript Aquestive Therapeutics Q1 2026 Earnings Preview Aquestive plans 75-rep Anaphylm launch and targets $46M-$50M in 2026 revenue while doubling medical affairs Read the full article on Seeking Alpha For further details see: Aquestive Therapeutics GAAP EPS of -$0.07 beats by $0.07, revenue of $14.4M beats by $3.5M